. . "Selecting Atypical Antipsychotic-Practical Issues"@en . "Praktick\u00E9 aspekty volby atypick\u00E9ho antipsychotika" . "24-30" . . . "1" . "Praktick\u00E9 aspekty volby atypick\u00E9ho antipsychotika" . . "Z(MSM 141100001)" . "100" . "RIV/00216224:14110/04:00021219" . . . . . "Praktick\u00E9 aspekty volby atypick\u00E9ho antipsychotika"@cs . . . "V sou\u010Dasn\u00E9 dob\u011B m\u00E1me k dispozici n\u011Bkolik atypick\u00FDch antipsychotik(antipsychotik druh\u00E9 generace), kter\u00E1 se li\u0161\u00ED hlavn\u011B profilem vedlej\u0161\u00EDch \u00FA\u010Dink\u016F. Sd\u011Blen\u00ED se soust\u0159e\u010Fuje na vedlej\u0161\u00ED \u00FA\u010Dinky, kter\u00E9 jsou p\u0159i volb\u011B atypick\u00E9ho antipsychotika v\u00FDznamn\u00E9. U ka\u017Ed\u00E9ho nemocn\u00E9ho,kter\u00FD je kandid\u00E1tem na l\u00E9\u010Dbu atypick\u00FDm antipsychotikem by m\u011Bla b\u00FDt stanovena n\u00E1chylnost k somatick\u00FDm probl\u00E9m\u016Fm. Detailn\u011B je rozeb\u00EDr\u00E1n p\u0159\u00EDr\u016Fstek hmotnosti, porucha gluk\u00F3zov\u00E9ho a lipidov\u00E9ho metabolismu a hyperprolaktin\u00E9mie. Z hlediska p\u0159\u00EDr\u016Fstku hmotnosti a vlivu na hladiny gluk\u00F3zy a lipid\u016F je nejrizikov\u011Bj\u0161\u00ED klozapin a olanzapin,z hlediska hyperprolaktin\u00E9mie risperidon a amisulprid. Na z\u00E1klad\u011B sou\u010Dasn\u00E9ho stavu znalost\u00ED je p\u0159i aplikaci klozapinu a olanzapinu \u017E\u00E1douc\u00ED tak\u00E9 pravideln\u011B sledov\u00E1n\u00ED glyk\u00E9mie a lipidov\u00E9ho spektra. P\u0159i aplikaci risperidonu a amisulpridu je nutno c\u00EDlen\u011B pr\u00E1trat po prolaktin-dependentn\u00EDch p\u0159\u00EDznac\u00EDch, a pokud jsou p\u0159\u00EDtomn\u00E9, je vhodn\u00E9 stanoven\u00ED prolaktin\u00E9mie. Jsou zm\u00EDn\u011Bny mo\u017Enosti prevence a l\u00E9\u010Dby uveden\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink"@cs . "1212-0383" . . "Selecting Atypical Antipsychotic-Practical Issues"@en . "1"^^ . "Praktick\u00E9 aspekty volby atypick\u00E9ho antipsychotika"@cs . . "RIV/00216224:14110/04:00021219!RIV08-MSM-14110___" . "CZ - \u010Cesk\u00E1 republika" . "Nowadays, we have at our disposal several atypical antipsychotics(antipsychotic of 2nd generation).There is a difference between them in the profile of side effects. The article focuses on side effects, which are important for selecting atypical antipsychotic. Every patient who is candidate for atypical antipsychotic must be assessed for his/her medical susceptibilities. In more detail the weight gain, abnormalities in glucose and lipid metabolism and hyperprolactinemia are discussed.Clozapine and olanzapine appear to slow the highest impact on weight gain and glucose and lipid levels,risperidone and amisulpride on prolactin levels.On the base of current knowledge during clozapine and olanzapine administration it is advisable to monitor blood glucose and lipid levels at regular periods. During risperidone and olanzapine administration it is necessary to search for prolactin-dependent side affects. If present, the prolactin level should be obtained. The possibilities of prevention and treatment of side"@en . "\u010Ce\u0161kov\u00E1, Eva" . "1"^^ . "[B9DBE34163C4]" . "atypical antipsychotic; side effect; weight gain; glucose intolerance; dyslipidemia; hyperprolactinemia"@en . . . "\u010Cesk\u00E1 a Slovensk\u00E1 psychiatrie" . . . "V sou\u010Dasn\u00E9 dob\u011B m\u00E1me k dispozici n\u011Bkolik atypick\u00FDch antipsychotik(antipsychotik druh\u00E9 generace), kter\u00E1 se li\u0161\u00ED hlavn\u011B profilem vedlej\u0161\u00EDch \u00FA\u010Dink\u016F. Sd\u011Blen\u00ED se soust\u0159e\u010Fuje na vedlej\u0161\u00ED \u00FA\u010Dinky, kter\u00E9 jsou p\u0159i volb\u011B atypick\u00E9ho antipsychotika v\u00FDznamn\u00E9. U ka\u017Ed\u00E9ho nemocn\u00E9ho,kter\u00FD je kandid\u00E1tem na l\u00E9\u010Dbu atypick\u00FDm antipsychotikem by m\u011Bla b\u00FDt stanovena n\u00E1chylnost k somatick\u00FDm probl\u00E9m\u016Fm. Detailn\u011B je rozeb\u00EDr\u00E1n p\u0159\u00EDr\u016Fstek hmotnosti, porucha gluk\u00F3zov\u00E9ho a lipidov\u00E9ho metabolismu a hyperprolaktin\u00E9mie. Z hlediska p\u0159\u00EDr\u016Fstku hmotnosti a vlivu na hladiny gluk\u00F3zy a lipid\u016F je nejrizikov\u011Bj\u0161\u00ED klozapin a olanzapin,z hlediska hyperprolaktin\u00E9mie risperidon a amisulprid. Na z\u00E1klad\u011B sou\u010Dasn\u00E9ho stavu znalost\u00ED je p\u0159i aplikaci klozapinu a olanzapinu \u017E\u00E1douc\u00ED tak\u00E9 pravideln\u011B sledov\u00E1n\u00ED glyk\u00E9mie a lipidov\u00E9ho spektra. P\u0159i aplikaci risperidonu a amisulpridu je nutno c\u00EDlen\u011B pr\u00E1trat po prolaktin-dependentn\u00EDch p\u0159\u00EDznac\u00EDch, a pokud jsou p\u0159\u00EDtomn\u00E9, je vhodn\u00E9 stanoven\u00ED prolaktin\u00E9mie. Jsou zm\u00EDn\u011Bny mo\u017Enosti prevence a l\u00E9\u010Dby uveden\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink" . "581108" . . "14110" . "7"^^ .